Provectus Pharmaceuticals
PVCT · OTC · United States
Share price · PVCT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PVCT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Apr 2026-12.3%
Nothing announced by PVCT that day or the session before.
- 7 Apr 2026+14.0%
Nothing announced by PVCT that day or the session before.
- 9 Feb 2026+15.8%
Nothing announced by PVCT that day or the session before.
- 6 Feb 2026-9.5%
Nothing announced by PVCT that day or the session before.
- 26 Jan 2026-13.8%
Nothing announced by PVCT that day or the session before.
- 2 Jan 2026+14.3%
Nothing announced by PVCT that day or the session before.
- 26 Nov 2025+18.5%
Nothing announced by PVCT that day or the session before.
- 25 Nov 2025-19.4%
Nothing announced by PVCT that day or the session before.
- 2 Oct 2025-13.6%
Nothing announced by PVCT that day or the session before.
- 25 Sep 2025+31.3%
Nothing announced by PVCT that day or the session before.
Share of unusual movement by asset
For each asset, the share of PVCT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
rose bengal disodiumNo recent activity | Phase 3 | —Small molecule | Melanoma Locally Advanced Cutaneous Melanoma |
PH-10No recent activity | Phase 2 | Photoactivated hydrogel (Rose Bengal disodium)Small molecule | Psoriasis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $0.2M | — | $1.3M-$0.9M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $0.1M | $1.2M | $1.0M-$0.4M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $0.3M | $0.2M | $1.3M-$0.4M operating cash flow | report ↗ |
| 2025-Q3 | — | $0.3M | $0.1M | $1.3M-$0.8M operating cash flow | report ↗ |
| 2025-Q2 | $0.1M | $0.9M | $0.4M | $1.8M-$0.5M operating cash flow | report ↗ |
| 2025-Q1 | $0.3M | $0.4M | $0.4M | $1.1M-$1.1M operating cash flow | report ↗ |
| 2024-Q3 | $0.1M | $0.4M | $0.2M | $1.0M-$0.6M operating cash flow | report ↗ |
| 2024-Q2 | $0.3M | $0.5M | <$0.1M | $0.8M-$0.8M operating cash flow | report ↗ |
| 2024-Q1 | $0.2M | $0.6M | <$0.1M | $0.5M-$1.0M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $0.3M | $0.4M | $0.8M-$0.8M operating cash flow | report ↗ |
| 2023-Q2 | $0.2M | $0.4M | $0.2M | $0.8M-$0.6M operating cash flow | report ↗ |
| 2023-Q1 | $0.2M | $0.6M | <$0.1M | $0.8M-$0.6M operating cash flow | report ↗ |
| 2022-Q3 | $0.3M | $0.6M | $0.1M | $0.7M-$0.8M operating cash flow | report ↗ |
| 2022-Q2 | $0.3M | $0.8M | $0.1M | $1.1M-$0.9M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $0.7M | $0.2M | $1.0M-$0.6M operating cash flow | report ↗ |
| 2021-Q3 | — | $0.6M | $0.3M | $1.1M-$0.7M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.3M | $1.9M | $0.3M | $1.4M-$3.3M operating cash flow | report ↗ |
For fiscal year 2025, Provectus Biopharmaceuticals reported revenue of $0.34M, down 45.2% YoY, with R&D spend of $1.9M, down 5.0% YoY. Cash and equivalents stood at $0.25M, and the company reported a net loss of $5.43M with a quarterly net burn of $5.43M.
The 10-K narrative describes Provectus as a clinical-stage biotechnology company developing rose bengal sodium-based immunotherapies, with clinical programs including intratumoral PV-10 for oncology, topical PH-10 for dermatology, and PV-305 for ophthalmology. The company highlighted ongoing non-clinical work in oral oncology, hematology, wound healing, and animal health, as well as one new U.S. patent award and several international patent grants during 2025. Plans include initiating new early-stage trials for penile squamous cell carcinoma and FOLRINOX-refractory pancreatic ductal adenocarcinoma, and advancing a systemically administered PV-10 formulation toward an IND filing.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.6M | $2.0M | $0.3M | $1.2M-$3.3M operating cash flow | report ↗ |
| 2023-FY | $0.6M | $1.8M | $0.1M | $0.8M-$2.6M operating cash flow | report ↗ |
| 2022-FY | $1.0M | $2.4M | <$0.1M | $0.9M-$3.0M operating cash flow | report ↗ |
| 2021-FY | — | $2.6M | $0.7M | $1.4M-$1.0M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | — | — | — | Form 4 |
| 2026-11-13 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | 11,328 | — | — | Form 4 |
| 2026-11-06 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | — | — | — | Form 4 |
| 2026-11-06 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | 13,216 | — | — | Form 4 |
| 2026-10-30 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | — | — | — | Form 4 |
| 2026-10-30 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | 24,544 | — | — | Form 4 |
| 2026-10-23 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | — | — | — | Form 4 |
| 2026-10-23 | Pershing Edward · director, CEO, 10% owner | Option exercise (derivative) | 7,599 | — | — | Form 4 |